Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived
Displaying 1 - 10 of 10 results

Giant Cell Arteritis

https://www.niams.nih.gov/health-topics/giant-cell-arteritis

What is giant cell arteritis? Giant cell arteritis causes the arteries of the scalp and neck to become red, hot, swollen, or painful. The arteries most affected are those in the temples on either side of the head. These arteries narrow, so not enough blood can pass through. It is important that you get treatment right away. Otherwise, the arteries could be permanently damaged. There is also a risk of blindness or stroke. If you have giant cell arteritis, your doctor should also look for signs of another disorder, polymyalgia rheumatica. These conditions often occur together.

Osteonecrosis

https://www.niams.nih.gov/health-topics/osteonecrosis

What is osteonecrosis? Osteonecrosis is a bone disease. It results from the loss of blood supply to the bone. Without blood, the bone tissue dies. This causes the bone to collapse. It may also cause the joints that surround the bone to collapse. If you have osteonecrosis, you may have pain or be limited in your physical activity. Osteonecrosis can develop in any bone, most often in the: Thigh bone (femur). Upper arm bone (humerus). Knees. Shoulders. Ankles. It is also called: Avascular necrosis. Aseptic necrosis. Ischemic necrosis.

Vitiligo

https://www.niams.nih.gov/health-topics/vitiligo

What is vitiligo? Vitiligo is a chronic (long-lasting) disorder that causes areas of skin to lose color. When skin cells that make color are attacked and destroyed, the skin turns a milky-white color. No one knows what causes vitiligo, but it may be an autoimmune disease. In people with autoimmune diseases, the immune cells attack the body’s own healthy tissues by mistake, instead of viruses or bacteria. A person with vitiligo sometimes may have family members who also have the disease. There is no cure for vitiligo, but treatment may help skin tone appear more even.

Epidermolysis Bullosa

https://www.niams.nih.gov/health-topics/epidermolysis-bullosa

What is epidermolysis bullosa? Epidermolysis bullosa is a group of rare diseases that cause fragile skin that leads to blisters and tearing. Tears, sores, and blisters in the skin happen when something rubs or bumps the skin. They can appear anywhere on the body. In severe cases, blisters may also develop inside the body. The symptoms of the disease usually begin at birth or during infancy and range from mild to severe.

Stem Cell-Based Strategies Offer Personalized Approaches For Treating Inherited Skin Disease

https://www.niams.nih.gov/newsroom/spotlight-on-research/stem-cell-based-strategies-offer

Two new studies funded in part by NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) describe efforts to develop stem cell-based approaches for treating Epidermolysis Bullosa (EB), a rare, genetic skin disease. The findings, which were published jointly in the journal, Science Translational Medicine, may lead to individualized therapies for EB, and possibly other genetic diseases. People with EB have skin that is so fragile that the slightest friction causes blisters. The severity of the disease ranges from limited tearing of skin on the hands and feet to widespread blistering and scarring, including mucosal surfaces like the

Ankylosing Spondylitis

https://www.niams.nih.gov/health-topics/ankylosing-spondylitis

What is ankylosing spondylitis? Ankylosing spondylitis is a type of arthritis that causes inflammation in certain parts of the spine. Over time, this inflammation in the joints and tissues of the spine can cause stiffness. In severe cases, this may cause the bones in the spine to grow together, which can lead to a rigid spine that is difficult to bend. Many people with ankylosing spondylitis have mild episodes of back pain and stiffness that come and go. But others have severe, ongoing back pain and stiffness. Other symptoms also may develop if other areas of the body are affected

Sjögren’s Syndrome

https://www.niams.nih.gov/health-topics/sjogrens-syndrome

What is Sjögren’s syndrome? Sjögren’s syndrome is a disease that affects the glands that make moisture. It most often causes dryness in the mouth and eyes. It can also lead to dryness in other places that need moisture, such as the nose, throat, and skin. Sjögren’s syndrome is also a rheumatic disease, which affect: Joints. Tendons. Ligaments. Bones. Muscles. The signs and symptoms of rheumatic diseases can include: Redness or heat. Swelling. Pain. Loss of function. Primary Versus Secondary Sjögren’s Syndrome Doctors have two categories for Sjögren’s syndrome: Primary form: Occurs if you do not have other rheumatic diseases. Secondary

Modified Protein Improves Vitiligo Symptoms in Mice

https://www.niams.nih.gov/newsroom/spotlight-on-research/modified-protein-improves-vitiligo-symptoms-mice

Altering a key protein involved in the development of vitiligo may protect against—or even reverse—the pigmentation loss associated with the skin disorder in mice, according to recent research funded by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, and published in the journal Science Translational Medicine. Vitiligo is a progressive autoimmune disease in which the skin cells that impart color (melanocytes) are destroyed, resulting in white patches on the face, hands and other parts of the body. Scientists are unsure what causes vitiligo. They are investigating the biological mechanisms that trigger the disease, as well as its

Same Immune Regulatory Protein Found to Play Instrumental Role in Two Hereditary Autoinflammatory Diseases

https://www.niams.nih.gov/newsroom/spotlight-on-research/same-immune-regulatory-protein-found

Research funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has revealed a new role for A20, a protein that regulates a key immune response pathway, in certain early-onset autoinflammatory diseases. The results suggest that targeting this pathway could be an effective strategy for treating these diseases, and possibly related conditions, as well.